

| | | | |
|---|------------------------|------------------------------|------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10722374 |
| | Filing Date | | 2003-11-25 |
| | First Named Inventor | David Bebbington | |
| | Art Unit | 1624 | |
| | Examiner Name | Venkataraman Balasubramanian | |
| | Attorney Docket Number | VPI/00-130-08 CON US | |

| U.S.PATENTS | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | 6653301 | B2 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | |
| | 2 | 6989385 | B2 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | |
| | 3 | 6664247 | B2 | 2003-12-16 | Bebbington et al. | |
| | 4 | 6653300 | B2 | 2003-11-25 | Bebbington et al. | |
| | 5 | 7087603 | B2 | 2006-08-08 | Bebbington et al. | |
| | 6 | 6656939 | B2 | 2003-12-02 | Bebbington et al. | |
| | 7 | 3755322 | | 1973-08-28 | Ciba-Geigy Corporation | |
| | 8 | 6841579 | B1 | 2005-01-11 | Sugen, Inc. | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|----------------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | | 1624 |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | | VPI/00-130-08 CON US |

| | | | | | | |
|--|----|---------|----|------------|--------------------------------------|--|
| | 9 | 3133081 | | 1964-05-12 | Smith Line & French Laboratories | |
| | 10 | 3935183 | | 1976-01-27 | Imperial Chemical Industries Limited | |
| | 11 | 3998951 | | 1976-12-21 | FMC Corporation | |
| | 12 | 4051252 | | 1977-09-27 | Bayer Aktiengesellschaft | |
| | 13 | 4493726 | | 1985-01-15 | Ciba Geigy Corporation | |
| | 14 | 5972946 | | 1999-10-26 | Dainippon Pharmaceutical Co., Ltd. | |
| | 15 | 6093716 | | 2000-07-25 | Celltech Therapeutics, Limited | |
| | 16 | 6277989 | B1 | 2001-08-21 | Scios, Inc. | |
| | 17 | 6579983 | B1 | 2003-06-17 | Celltech R&D Limited | |
| | 18 | 6660731 | B2 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | |
| | 19 | 6184226 | B1 | 2001-02-06 | Scios Inc. | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|----------------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | | 1624 |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | | VPI/00-130-08 CON US |

| | | | | | | |
|--|----|---------|----|------------|--------------------------------------|--|
| | 20 | 6589958 | B1 | 2003-07-08 | Bristol-Myers Squibb Pharma Company | |
| | 21 | 7008948 | B2 | 2006-03-07 | Vertex Pharmaceuticals, Incorporated | |
| | 22 | 6696452 | B2 | 2004-02-24 | Vertex Pharmaceuticals Incorporated | |
| | 23 | 7098330 | B2 | 2006-08-29 | Vertex Pharmaceuticals Incorporated | |
| | 24 | 6660731 | B2 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | |
| | 25 | 6613776 | B2 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | |
| | 26 | 6638926 | B2 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | |
| | 27 | 6610677 | B2 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | |
| | 28 | 7115739 | B2 | 2006-10-03 | Vertex Pharmaceuticals Incorporated | |
| | 29 | 7179826 | B2 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | |
| | 30 | 6846928 | B2 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|----------------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | | 1624 |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | | VPI/00-130-08 CON US |

| | | | | | |
|----|---------|----|------------|--------------------------------------|--|
| 31 | 7091343 | B2 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | |
| 32 | 4540698 | | 1985-09-10 | Mitsui Toatsu Chemicals Incorporated | |
| 33 | 4711951 | | 1987-12-08 | Pharmacia Aktiebolag | |
| 34 | 5124441 | | 1992-06-23 | Pharmacia Aktiebolag | |
| 35 | 6562971 | B2 | 2003-05-13 | BASF Aktiengesellschaft | |

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | 20020065270 | A1 | 2002-05-30 | Bristol-Myers Squibb Company | |
| | 2 | 20010018436 | A1 | 2001-08-30 | Tularik Inc. | |
| | 3 | 20020052386 | A1 | 2002-05-02 | Armistead et al. | |
| | 4 | 20030004164 | A1 | 2003-01-02 | Bebbington et al. | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|----------------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | | 1624 |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | | VPI/00-130-08 CON US |

| | | | | | |
|----|-------------|----|------------|--------------------|--|
| 5 | 20050038023 | A1 | 2005-02-17 | Bebbington et al. | |
| 6 | 20040214814 | A1 | 2004-10-28 | Bebbington et al. | |
| 7 | 20030105090 | A1 | 2003-06-05 | Bebbington et al. | |
| 8 | 20040157893 | A1 | 2004-08-12 | Bebbington et al. | |
| 9 | 20030069239 | A1 | 2003-04-10 | Cytovia, Inc. | |
| 10 | 20030069248 | A1 | 2003-04-10 | Chakravarty et al. | |
| 11 | 20030087922 | A1 | 2003-05-08 | Bethiel et al. | |
| 12 | 20030187002 | A1 | 2003-10-02 | Mortlock et al. | |
| 13 | 20060270660 | A1 | 2006-11-30 | Charrier et al. | |
| 14 | 20030064982 | A1 | 2003-04-03 | Davies et al. | |
| 15 | 20040009981 | A1 | 2004-01-15 | Bebbington et al. | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | 1624 | |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | VPI/00-130-08 CON US | |

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|-----------------------------|------------------------|------------------|---|--|-------------------------------------|
| | 1 | 0136976 | EP | A2 | 1985-04-10 | Ciba-Geigy AG | | <input type="checkbox"/> |
| | 2 | 0012497 | WO | A2 | 2000-03-09 | Scios Inc. | | <input type="checkbox"/> |
| | 3 | 0144242 | WO | A1 | 2001-06-21 | Bristol-Myers Squibb Co. | | <input type="checkbox"/> |
| | 4 | 0247690 | WO | A1 | 2002-06-20 | Cytovia, Inc. | | <input checked="" type="checkbox"/> |
| | 5 | 0224667 | WO | A1 | 2002-03-28 | Merck Patent GMBH | | <input type="checkbox"/> |
| | 6 | 9614843 | WO | A2 | 1996-05-23 | Cor Therapeutics, Inc. | | <input type="checkbox"/> |
| | 7 | 9509851 | WO | A1 | 1995-04-13 | Ciba-Geigy AG | | <input type="checkbox"/> |
| | 8 | 9709325 | WO | A1 | 1997-03-13 | Signal Pharmaceuticals, Inc. | | <input type="checkbox"/> |
| | 9 | 9719065 | WO | A1 | 1997-05-29 | Celltech Therapeutics Limited | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | 1624 | |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | VPI/00-130-08 CON US | |

| | | | | | | | | |
|--|----|---------|----|----|------------|-------------------------------------|--|--------------------------|
| | 10 | 9811095 | WO | A1 | 1998-03-19 | Celltech Therapeutics Limited | | <input type="checkbox"/> |
| | 11 | 9941253 | WO | A1 | 1999-08-19 | Tularik Inc. | | <input type="checkbox"/> |
| | 12 | 0140215 | WO | A1 | 2001-06-07 | Pfizer Products Inc. | | <input type="checkbox"/> |
| | 13 | 0147879 | WO | A1 | 2001-07-05 | Icos Corporation | | <input type="checkbox"/> |
| | 14 | 0179198 | WO | A1 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | | <input type="checkbox"/> |
| | 15 | 0160816 | WO | A1 | 2001-08-23 | Amgen Inc. | | <input type="checkbox"/> |
| | 16 | 0039101 | WO | A1 | 2000-07-06 | AstraZeneca UK Limited | | <input type="checkbox"/> |
| | 17 | 0164655 | WO | A1 | 2001-09-07 | AstraZeneca AB | | <input type="checkbox"/> |
| | 18 | 0413140 | WO | A1 | 2004-02-12 | Vertex Pharmaceuticals Incorporated | | <input type="checkbox"/> |
| | 19 | 0250065 | WO | A2 | 2002-06-27 | Vertex Pharmaceuticals Incorporated | | <input type="checkbox"/> |
| | 20 | 0250066 | WO | A2 | 2002-06-27 | Vertex Pharmaceuticals Incorporated | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | 1624 | |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | VPI/00-130-08 CON US | |

| | | | | | | | | |
|--|----|---------|----|----|------------|--|--|--------------------------|
| | 21 | 0222601 | WO | A1 | 2002-03-21 | Vertex Pharmaceuticals Incorporation | | <input type="checkbox"/> |
| | 22 | 0279197 | WO | A1 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | | <input type="checkbox"/> |
| | 23 | 0400833 | WO | A1 | 2003-12-31 | Vertex Pharmaceuticals Incorporated | | <input type="checkbox"/> |
| | 24 | 9208715 | WO | A1 | 1992-05-29 | Nissan Chemical Industries, Ltd. | | <input type="checkbox"/> |
| | 25 | 9322681 | WO | A1 | 1993-11-11 | Neurogen Corporation | | <input type="checkbox"/> |
| | 26 | 9515758 | WO | A1 | 1995-06-15 | Rhonepoulenc Rorer Pharmaceuticals Inc. | | <input type="checkbox"/> |
| | 27 | 9802434 | WO | A1 | 1998-01-22 | Glaxo Group Limited | | <input type="checkbox"/> |
| | 28 | 9814450 | WO | A1 | 1998-04-09 | Novartis AG | | <input type="checkbox"/> |
| | 29 | 9816502 | WO | A1 | 1998-04-23 | Warner-Lambert Company | | <input type="checkbox"/> |
| | 30 | 9947154 | WO | A1 | 1999-09-23 | Cytovia, Inc. | | <input type="checkbox"/> |
| | 31 | 9962518 | WO | A1 | 1999-12-09 | Cadus Pharmaceutical Corporation | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|------------------------------|
| Application Number | 10722374 |
| Filing Date | 2003-11-25 |
| First Named Inventor | David Bebbington |
| Art Unit | 1624 |
| Examiner Name | Venkataraman Balasubramanian |
| Attorney Docket Number | VPI/00-130-08 CON US |

| | | | | | | | |
|----|---------|----|----|------------|-------------------------------------|--|--------------------------|
| 32 | 0042029 | WO | A1 | 2000-07-20 | Warner-Lambert Company | | <input type="checkbox"/> |
| 33 | 0059509 | WO | A1 | 2000-10-12 | Novartis AG | | <input type="checkbox"/> |
| 34 | 0078757 | WO | A1 | 2000-12-28 | Shionogi Bioresearch Corp. | | <input type="checkbox"/> |
| 35 | 0112621 | WO | A1 | 2001-02-22 | Vertex Pharmaceuticals Incorporated | | <input type="checkbox"/> |
| 36 | 0139777 | WO | A1 | 2001-06-07 | OSI Pharmaceuticals, Inc. | | <input type="checkbox"/> |
| 37 | 0302312 | EP | A2 | 1989-02-08 | Bayer AG | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|---|--------------------------|
| | 1 | Wiener, J.R. et al., "Decreased Src Tyrosine Kinase Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a Nude Mouse Model," Clinical Cancer Research, 5, 2164-2170 (1999). | <input type="checkbox"/> |
| | 2 | Warner, S.L. et al, "Targeting Aurora-2 Kinase in Cancer," Mol. Cancer Thera., 2, 589-585, 2003. | <input type="checkbox"/> |
| | 3 | Wagman, A.S. et all, "Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes," Current Pharmaceutical Design, 10, 1105-1137 (2004). | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|----------------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | | 1624 |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | | VPI/00-130-08 CON US |

| | | |
|----|--|-------------------------------------|
| 4 | Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 2. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxydimidines and Analogues," Pestic. Sci., 47: 115-124 (1996). | <input type="checkbox"/> |
| 5 | Tanaka, T.U. et al., "Evidence that the Ipl1-Sli15 (Aurora Kinase-INCENP) Complex Promotes Chromosome Bi-orientation by Altering Kinetochore-Spindle Pole Connections," Cell, 108, 317-329 (2002). | <input type="checkbox"/> |
| 6 | Staley, C.A. et al., "Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific for c-Src," Cell Growth & Differentiation, 8: 269-274 (1997). | <input type="checkbox"/> |
| 7 | Soriano, P. et al., "Targeted Disruption of the C-SIC PmtO-Oncogene Leads to Osteopetrosis in Mice," Cell, 64: 693-702, (1991). | <input type="checkbox"/> |
| 8 | Campbell, S.F. et al., "2,4-Diamino-6,7-dimethoxyquinazolines. 3.2-(4-Heterocyclyl)piperazin-1-yl) Derivatives as α 1-Adrenoceptor Antagonists and Antihypertensive Agents," J. Med. Chem., 30, 1794-1798 (1987). | <input type="checkbox"/> |
| 9 | Casanova, B. et al., "Revisión crítica de la patogenia actual de la esclerosis múltiple y futuras direcciones posibles," Rev. Neurol., 28 (9): 909-915 (1999). | <input checked="" type="checkbox"/> |
| 10 | Cline, G.W. et al., "Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats," Diabetes, 51, 2903-2910 (2002). | <input type="checkbox"/> |
| 11 | Simone, J.V., "Oncology: Introduction" in Cecil Textbook in Medicine, 20th ed., Vol. 1, 1004-1010 (1996). | <input type="checkbox"/> |
| 12 | Coleman, R.A., "The Biological Evaluation of New Compounds" in Medicinal Chemistry: Principles and Practice, King, Frank D. ed, Royal Society of Chemistry, 53-66 (1994). | <input type="checkbox"/> |
| 13 | The CONDENSED CHEMICAL DICTIONARY, Sixth Edition by Arthur and Elizabeth Rose, 38 (1961). | <input type="checkbox"/> |
| 14 | Damasio, A.R., "Alzheimer's Disease and Related Dementia," in Cecil Textbook of Medicine, 20th ed., 2: 1992-1996 (1996). | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|------------------------------|------------|
| Application Number | | 10722374 |
| Filing Date | | 2003-11-25 |
| First Named Inventor | David Bebbington | |
| Art Unit | 1624 | |
| Examiner Name | Venkataraman Balasubramanian | |
| Attorney Docket Number | VPI/00-130-08 CON US | |

| | | |
|----|---|--------------------------|
| 15 | Rogers, E. et al., "The aurora kinase AIR-2 functions in the release of chromosome cohesion in Caenorhabditis elegans meiosis," J. Cell Biol., 157(2): 219–229 (2002). | <input type="checkbox"/> |
| 16 | Fisher A., "Therapeutic Strategies in Alzheimer's Disease: M1 Muscarinic Agonists," Jpn. J. Pharmacol., 84(2):101-12 (2000). | <input type="checkbox"/> |
| 17 | Frame, M.C., "Src in cancer: deregulation and consequences for cell behaviour," Biochimica et Biophysica Acta 1602, 114– 130 (2002). | <input type="checkbox"/> |
| 18 | Frampton, J.E. et al., "Pentoxifylline (Oxpentifylline) - A Review of its Therapeutic Efficacy in the Management of Peripheral Vascular and Cerebrovascular Disorder," Drugs & Aging, 7(6): 480-503 (1995). | <input type="checkbox"/> |
| 19 | Ganellin, C.R., "Past Approaches to Discovering New Drugs as Medicines" in Medicinal Chemistry, Principles and Practices. King, Frank D. ed, Royal Society of Chemistry, 189-205 (1994). | <input type="checkbox"/> |
| 20 | Hamdane, M. et al., "A Therapeutic Target in Alzheimer Neurodegeneration," J. Mol. Neurosci., 19(3): 275-87 (2002). | <input type="checkbox"/> |
| 21 | Hardt, S.E. et al., "Glycogen Synthase Kinase-3 β - A Novel Regulator of Cardiac Hypertrophy and Development," Circulation Research, 90: 1055-1063 (2002). | <input type="checkbox"/> |
| 22 | Parnell, E.W., "2-Cyano-4-nitrophenylhydrazine and 3-Amino-5-nitroindazole", J. Chem. Soc., 2363-2365 (1959). | <input type="checkbox"/> |
| 23 | Heaney, F. et al., "Pyrimidine annelated heterocycles—synthesis and cycloaddition of the first pyrimido[1,4]diazepine N-oxides," J. Chem. Soc., Perkin Trans. 1, 622–632 (2001). | <input type="checkbox"/> |
| 24 | Hendriksen, E.J. et al., "Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats," Am. J. Physiol. Endocrinol. Metab., 284: E892–E900 (2003). | <input type="checkbox"/> |
| 25 | Okafor, C.O., "Studies in the Heterocyclic Series. X. 1,3,9-Triazaphenothiazine Ring System, a New Phenothiazine Ring," J. Org. Chem., 40(19): 2753-2755 (1975). | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|------------------------------|
| Application Number | 10722374 |
| Filing Date | 2003-11-25 |
| First Named Inventor | David Bebbington |
| Art Unit | 1624 |
| Examiner Name | Venkataraman Balasubramanian |
| Attorney Docket Number | VPI/00-130-08 CON US |

| | | |
|----|--|--------------------------|
| 26 | Jambhekar, S.S., "Biopharmaceutical Properties of Drug Substances" in Principles of Medicinal Chemistry, 4th ed., 12-24, (1995). | <input type="checkbox"/> |
| 27 | Layzer, R.B., "Section Five - Degenerative Diseases of the Nervous System" in Cecil Textbook of Medicine, 20th ed., 2: 2050-2057 (1996). | <input type="checkbox"/> |
| 28 | Lee, S.J. et. al., "Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities," J. Med. Chem., 38 (18): 3547-3557 (1995). | <input type="checkbox"/> |
| 29 | Medwid, J.B. et al., "Preparation of Triazolo[1,5-c]pyrimidines as Potential Antiasthma Agents," J. Med. Chem. 33, 1230-1241 (1990). | <input type="checkbox"/> |
| 30 | Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 1. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxy pyrimidines and Analogues," Pestic. Sci., 47: 103-113 (1996). | <input type="checkbox"/> |
| 31 | Gnecco, D. et al., "An Improved Preparation of 1-Methyl-4-Cyano-4-phenylpiperidine", Org. Prep. Proced. Int., 18 (4), 478-480 (1996). | <input type="checkbox"/> |
| 32 | Fedorynski, M. et al., "Synthesis of 1-Arycyclopropanecarbonitriles under Phase-transfer Catalytic Conditions", Org. Prep. Proced. Int., 27(3), 355-359 (1995). | <input type="checkbox"/> |
| 33 | Suzuki, S. et al., "Application of electrogenerated triphenylmethyl anion as a base for alkylation of arylacetic esters and arylacetonitriles and isomerization of allylbenzenes", Can. J. Chem., 72(2): 357-361 (1994). | <input type="checkbox"/> |
| 34 | Prasad, G. et al., "18-Crown-6 as a catalyst in the dialkylation of o-nitrophenacyl derivatives", J. Org. Chem., 25, 7188-7190 (1991). | <input type="checkbox"/> |
| 35 | Moss, R.A. et al., "Conversion of 'Obstinate' Nitriles to Amidines by Garigipati's Reaction", Tetrahedron Lett., 36(48), 8761-8764 (1995). | <input type="checkbox"/> |
| 36 | Garigipati, R.S., "An efficient conversion of nitriles to amidines", Tetrahedron Lett., 31(14), 1969-1972 (1990). | <input type="checkbox"/> |

| | | | |
|---|------------------------|------------------------------|------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10722374 |
| | Filing Date | | 2003-11-25 |
| | First Named Inventor | David Bebbington | |
| | Art Unit | 1624 | |
| | Examiner Name | Venkataraman Balasubramanian | |
| | Attorney Docket Number | VPI/00-130-08 CON US | |

| | | | | |
|--|--|--|--|-----------------|
| If you wish to add additional non-patent literature document citation information please click the Add button | | | | Add |
| EXAMINER SIGNATURE | | | | |
| Examiner Signature | | | | Date Considered |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | | |
| <p>¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.</p> | | | | |